Original from: Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination with everolimus for the treatment of adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorised test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.
The approval of Wilserdly addresses an important unmet need for patients developing resistance. Up to 40% of patients with hormone receptor (HR)-positive metastatic breast cancer develop ESR1 mutations that drive resistance and disease progression. Wilserdly plus everolimus addresses this by targeting two different signalling pathways while helping to minimise the impact of treatment on people’s lives as an oral regimen without the need for injections.
"For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge - often requiring more intensive treatment,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home.”
The FDA approval is supported by positive primary endpoint data from the phase III evERA Breast Cancer study published in The New England Journal of Medicine. In adult patients with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer progressing after prior cyclin-dependent kinase (CDK)4/6 inhibitor therapy, the all-oral combination of Wilserdly plus everolimus significantly prolonged progression-free survival, achieving a 62% reduction in the risk of disease progression or death compared to standard endocrine therapy plus everolimus (stratified hazard ratio=0.38; 95% confidence interval: 0.27–0.54; p<0.0001).
“Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow,” said Dr Erica L. Mayer, Director of Breast Cancer Clinical Research at the Dana-Farber Cancer Institute. “The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option.”
“For more than three decades, Roche has transformed care across oncology, and this first approval for Wilserdly marks a pivotal leap forward in addressing aggressive, treatment-resistant breast cancer,” said Teresa Graham, Chief Executive Officer, Roche Pharmaceuticals. “We remain focused on maximising the clinical impact of Wilserdly across the continuum of care, including early-stage disease.”
Roche has also submitted a New Drug Application for Wilserdly as an adjuvant treatment for adults with ER-positive, HER2-negative, stage I, II, and III breast cancer at intermediate to high risk of recurrence based on the phase III lidERA Breast Cancer study, which was accepted under Priority Review. The FDA has set a Prescription Drug User Fee Act date of 30 November 2026. If approved, this would represent the first new adjuvant endocrine therapy in over 20 years, with potential to establish a new standard of care in this setting.
Roche’s broad and robust Wilserdly clinical development programme spans distinct treatment settings and lines of therapy, reflecting our commitment to deliver innovative medicines to as many people with HR-positive breast cancer as possible. Additional regulatory filings and development activities are underway in markets outside the US.
Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.